TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Alzai Health Corp. (TSXV:ALZI) ("Alzai" or the "Corporation") is pleased to announce that it has obtained a receipt for its final long form prospectus dated April 21, 2026 (the "Prospectus") filed with the securities regulatory authorities in British Columbia, Alberta and Ontario for an initial public offering of a minimum of 8,000,000 units of the Corporation (the "Units") and up to a maximum of 10,000,000 Units at a price of $0.40 per Unit for gross proceeds of a minimum of $3,200,000 and a maximum of $4,000,000 (the "Offering").
Each Unit consists of one common share in the authorized share structure of the Corporation (a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share (a "Warrant Share") at a price of $0.60 per Warrant Share for a period of 24 months following the Closing Date (as defined herein).
The warrants are subject to an acceleration right held by the Corporation, such that in the event that the closing price of the Corporation's shares on the TSX Venture Exchange ("TSXV") is equal to or greater than $0.90 for any 10 consecutive trading day period, the Corporation may provide notice to the holders of the Warrants that the expiry time of the Warrants shall be accelerated to the date which is 30 days from the date of such notice, subject to the approval of the TSXV.
Haywood Securities Inc. (the "Agent") is acting as the exclusive agent for the ...
